Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
PSP-corticobasal syndrome (PSP-CBS) is an atypical variant of progressive supranuclear palsy (PSP), a rare late-onset neurodegenerative disease.
Biomarker and diagnostic research for progressive supranuclear palsy-corticobasal syndrome has been reported in the published literature.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
No clinical trials have been registered for progressive supranuclear palsy-corticobasal syndrome.
35 publications have been identified in PubMed for progressive supranuclear palsy-corticobasal syndrome. Research spans Epidemiology / Natural History (31%), Review / Meta-Analysis (29%), and Diagnostic / Biomarker (17%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 11 | 31% |
Data assembled from 3 of 12 sources · Last updated Nov 4, 2026, 5:22 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries |
10 |
29% |
Testing and diagnosis research | 6 | 17% |
Patient case studies | 3 | 9% |
Clinical study results | 3 | 9% |
Laboratory research | 2 | 6% |
Rodriguez-Porcel F (2026). [PMID: 41518136](https://pubmed.ncbi.nlm.nih.gov/41518136/). *Mov Disord Clin Pract*. [Review / Meta-Analysis]
Wang AC (2026). [PMID: 41562273](https://pubmed.ncbi.nlm.nih.gov/41562273/). *Mov Disord*. [Basic Science / Preclinical]
Wu LY (2026). [PMID: 41929290](https://pubmed.ncbi.nlm.nih.gov/41929290/). *medRxiv : the preprint server for health sciences*. [Basic Science / Preclinical]
Kukkle PL (2026). [PMID: 40898879](https://pubmed.ncbi.nlm.nih.gov/40898879/). *Movement disorders clinical practice*. [Review / Meta-Analysis]
Schmidt M (2026). [PMID: 41769249](https://pubmed.ncbi.nlm.nih.gov/41769249/). *Clinical parkinsonism & related disorders*. [Clinical Trial Publication]
McFarland NR (2025). [PMID: 40748119](https://pubmed.ncbi.nlm.nih.gov/40748119/). *Continuum (Minneapolis, Minn.)*. [Review / Meta-Analysis]
Ono Y (2025). [PMID: 39843325](https://pubmed.ncbi.nlm.nih.gov/39843325/). *Parkinsonism & related disorders*. [Epidemiology / Natural History]
Angel MJ (2025). [PMID: 40495913](https://pubmed.ncbi.nlm.nih.gov/40495913/). *Clinical parkinsonism & related disorders*. [Diagnostic / Biomarker]
Vaughan DP (2025). [PMID: 40138021](https://pubmed.ncbi.nlm.nih.gov/40138021/). *Journal of neurology*. [Epidemiology / Natural History]
Urso D (2025). [PMID: 40920400](https://pubmed.ncbi.nlm.nih.gov/40920400/). *JAMA neurology*. [Review / Meta-Analysis]
AI-curated news mentioning progressive supranuclear palsy-corticobasal syndrome
Updated Oct 9, 2026
A recent review highlights the longitudinal cognitive decline in patients with progressive supranuclear palsy, providing critical insights into disease progression. This evidence may inform future therapeutic strategies and patient management.
A recent case-control study investigates the prevalence of intestinal methanogen overgrowth in patients with progressive supranuclear palsy. This research adds to the understanding of gastrointestinal issues associated with this neurodegenerative disease.
A study published in PubMed examines groaning in patients with progressive supranuclear palsy, providing insights from a large Asian cohort. The findings may enhance understanding of this symptom in the context of the disease.